Home
iTeos Therapeutics

iTeos Therapeutics Market Share Analysis for August 2026

iTeos Therapeutics is pioneering the discovery and development of highly differentiated immuno-oncology therapeutics for cancer patients.

Health > Biotechnology and Pharmaceuticals

Domainiteostherapeutics.com

Year Founded2011

Employees51 - 200

Annual Revenue$100M - $200M

iTeos Therapeutics

iTeos Therapeutics (including company regionals)

iteostherapeutics.com

See more website traffic and engagement information

iTeos Therapeutics Revenue up to August 2026 is 100M - 200M

revenue generated by iTeos Therapeutics top domains

iTeos Therapeutics top domains revenue over 3 years

Revenue for iTeos Therapeutics top domains

iteostherapeutics.com100M - 200M

See more with Sales Intelligence

Total visits to iTeos Therapeutics's top domains

Understand iTeos Therapeutics market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in iTeos Therapeutics's top domains

Analyze iTeos Therapeutics engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on iTeos Therapeutics's top domains

See how iTeos Therapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

iTeos Therapeutics top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by iTeos Therapeutics

These are the website technologies, by industry, used by iTeos Therapeutics top domains

Content Management System (4)

WordPress

Widget (4)

Twemoji

Advertising (2)

PubMatic

Mobile (2)

Meta Viewport

More Technologies

7

See all

News & Signals from iTeos Therapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsMichel Detheux left iTeos Therapeutics SA as President & CEO on Jun 30th '26.After leading Muna's evolution into a clinical-stage company, Rita Balice-Gordon, Ph.D., will step down and join the Board of Directors; former iTeos President & CEO Michel Detheux, Ph.D., appointed Chief Executive Officer

NewsMcGrath leaves iTeos Therapeutics SA as Chief Scientific Officer.Prior to joining Enodia, Dr. McGrath served as Chief Scientific Officer of iTeos Therapeutics, where she led a team of discovery scientists and provided translational leadership to advance immuno-oncology therapies into clinical development.

NewsiTeos Therapeutics SA has issues with anti-TIGIT antibody belrestotug.It is no longer investing in the anti-TIGIT antibody belrestotug, which it was developing alongside iTeos Therapeutics.